Differences in baseline characteristics between patients with psoriasis and controls before and after propensity score matching (PSM)
| Before PSM | After PSM | |||||||
| Control group, n=82 430* | Psoriasis group, n=29 949* | P value† | SMD | Control group, n=21 138* | Psoriasis group, n=21 138* | P value† | SMD | |
| Sex | <0.001 | 0.067 | <0.001 | 0.046 | ||||
| Female | 37 616 (45.6) | 12 677 (42.3) | 9938 (47.0) | 9449 (44.7) | ||||
| Male | 44 814 (54.4) | 17 272 (57.7) | 11 200 (53.0) | 11 689 (55.3) | ||||
| Age (mean (SD)) | 46.86 (16.81) | 43.54 (16.55) | <0.001 | 0.199 | 45.37 (16.40) | 45.37 (16.40) | 1 | <0.001 |
| Type of payouts | <0.001 | 0.255 | 0.029 | 0.026 | ||||
| Medical insurance payouts | 68 095 (82.6) | 27 295 (91.1) | 18 601 (88.0) | 18 504 (87.5) | ||||
| Off-site medical insurance payouts | 987 (1.2) | 159 (0.5) | 116 (0.5) | 157 (0.7) | ||||
| Self-paying | 13 348 (16.2) | 2495 (8.3) | 2421 (11.5) | 2477 (11.7) | ||||
| Hospital grade | <0.001 | 0.209 | 0.093 | 0.016 | ||||
| Tertiary hospital (%) | 65 452 (79.4) | 26 104 (87.2) | 17 436 (82.5) | 17 303 (81.9) | ||||
| Non-tertiary hospital (%) | 16 978 (20.6) | 3845 (12.8) | 3702 (17.5) | 3835 (18.1) | ||||
*n (%).
†Wilcoxon rank-sum test. The χ2 test of independence.
SMD, standardised mean difference.